[Drug-induced crystalluria: myths and realities].
Medicinal crystalluria is often difficult to recognize and identify. Whether due to therapeutic overdoses or individual susceptibility, the diagnosis is always important. 70% of the drugs involved in crystalluria can induce kidney stones or promote their growth. In addition, approximately one medicinal crystalluria out of ten is clinically or biologically accompanied by kidney failure. On the basis of 59 cases of medicinal crystalluria, the means of identification, the molecules involved and the frequency of these iatrogenic crystalluria is discusses.
D003460:Crystallization; D006038:Glyoxylates / Q000009:adverse effects; D006801:Humans; D008859:Microscopy, Polarization; D011621:Pteridines / Q000009:adverse effects; D011804:Quinolines / Q000009:adverse effects; D013055:Spectrophotometry, Infrared; D013449:Sulfonamides / Q000009:adverse effects; D014545:Urinary Calculi / Q000139:chemically induced* / Q000652:urine; D001618:beta-Lactamases / Q000009:adverse effects
D006038:Glyoxylates; D011621:Pteridines; D011804:Quinolines; D013449:Sulfonamides; D001618:beta-Lactamases
Cristalluries médicamenteuses: mythes et réalités.